A Panel of Five-lncRNA Signature as a Potential Biomarker for Predicting Survival in Gastric and Thoracic Cancers

Abstract

Dysfunctional long non-coding RNAs (lncRNAs) have been found to have carcinogenic and/or tumor inhibitory effects in the development and progression of cancer, suggesting their potential as new independent biomarkers for cancer diagnosis and prognosis. The exploration of the relationship between lncRNAs and the overall survival (OS) of different cancers opens up new prospects for tumor diagnosis and treatment. In this study, we established a five-lncRNA signature and explored its prognostic efficiency in gastric cancer (GC) and several thoracic malignancies, including breast invasive carcinoma (BRCA), esophageal carcinoma, lung adenocarcinoma, lung squamous cell carcinoma (LUSC), and thymoma (THYM). Cox regression analysis and lasso regression were used to evaluate the relationship between lncRNA expression and survival in different cancer datasets from GEO and TCGA. Kaplan-Meier survival curves indicated that risk scores characterized by a five-lncRNA signature were significantly associated with the OS of GC, BRCA, LUSC, and THYM patients. Functional enrichment analysis showed that these five lncRNAs are involved in known biological pathways related to cancer pathology. In conclusion, the five-lncRNA signature can be used as a prognostic marker to promote the diagnosis and treatment of GC and thymic malignancies.

The Target E2F Family Gene PTTG1 for Prediction of Distant Relapse-Free Survival in Breast Cancer Patients Receiving Taxane and Anthracycline-Based NACT

“…High-throughput genomic studies provided cutting-edge sights into the molecular mechanisms and identi ed new potential targets of breast cancer [33][34][35][36]. Nevertheless, using a single biomarker for predicting often relatively lower predictive effects, and a risk model for predicting the OS and DRFS of patients [37][38][39][40][41][42][43] and a nomogram were popular which showed superior predictive effects as a better alternative [18, [44][45][46]. Meanwhile E2F related genes had been selected to build a model for predict the DRFS of breast cancer patients [47].…”

Phosphoserine phosphatase as a prognostic biomarker in patients with gastric cancer and its potential association with immune cells

“…Lauren’s classification is the most useful and widely applicable classification for pathology, generally dividing the disease into intestinal-, diffuse-, and mixed-subtype [ 4 ]. Although a few of molecular biomarkers have been used for predicting prognosis to date [ 5 , 6 ], few of clinical and prognostic biomarkers are available in gastric cancer. Therefore, searching biomarkers for prognosis prediction in gastric cancer patients could be helpful in deciding more effective clinical regimen.…”

Thymic epithelial tumors: examining the GTF2I mutation and developing a novel prognostic signature with LncRNA pairs to predict tumor recurrence

“…As lncRNAs and GTF2I are both important in TETs, it is critical to determine whether lncRNAs associated with GTF2I mutations in TETs. Previous studies have established lncRNA signatures based on lncRNA expression levels to predict the prognosis of patients with TETs [ 20 , 21 ]. However, the expression level of lncRNA depends on the detection platform; therefore, clinical utilization of these lncRNA signatures is limited by the accuracy of the detected lncRNA level.…”